The Weill Cornell Medicine (WCM) SPORE consists of three Projects focused on highly translational areas relevant to the detection and treatment of aggressive prostate cancer (PCa).
- Project 1: Targeting the synergistic role of DNA methylation and EZH2 activity in castration resistant prostate cancer
- Project 2: Targeting de novo lipogenesis in advanced prostate cancer
- Project 3: Identifying and overcoming resistance to 177Lu-PSMA
Together, these three innovative, high impact projects that comprise this SPORE will explore novel areas of therapeutic resistance that will be immediately clinically translatable, defining novel predictive biomarkers for currently clinical utilized agents whose resistance patterns are still poorly understood, while at the same time building mechanistic insight to the underlying biology, thereby exposing new therapeutic targets.
